Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,770.00down ₹7.70 (0.43%)BSE ₹1,768.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,777.70.
2 Nov: open ₹1,770.00, high ₹1,776.20, low ₹1,722.00
52-week range of traded prices to 2 Nov 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,24,682 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.73
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.76
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 34,57,791
Sun Pharmaceutical Industries orders, deals and press releases
527 filed, newest first. Page 7 of 11.
Feb 2016
Jan 2016
Dec 2015
Nov 2015
Oct 2015
31 Oct · Business
Sep 2015
Aug 2015
Jul 2015
Jun 2015
May 2015
Apr 2015
Mar 2015
Feb 2015
Dec 2014
1 Dec · Business
Sun Pharmaceuticals Industries Limited had informed the Exchange vide announcement dated November 24, 2014 regarding the Approval of Scheme of Arrangement between Ranbaxy Laboratories Limited with Sun Pharmaceutical Industries Ltd in the nature of merger of Ranbaxy Laboratories Limited with the Company. The Company has now informed that Foreign Investment Promotion Board (FIPB) has, as per the press release dated November 28, 14 released by FIPB unit of Ministry of Finance, Department of Economic Affairs, approved the proposal of the Company for issuing equity shares of the Company to the non-resident investors of Ranbaxy Laboratories Limited pursuant to the merger of Ranbaxy Laboratories Limited into Sun Pharmaceutical Industries Limited through the scheme of arrangement between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Limited.
Nov 2014
13 Nov · Business
Board of Directors has passed Resolution at their meeting held on November 13, 2014 approving subject to the approval of SEBI, Stock Exchanges the High Court of Gujarat at Ahmedabad, Shareholders and Creditors of the Company and other required governmental and / or regulatory authorities, as may be applicable and required the Scheme of Amalgamation under Sections 391 to 394 of the Companies Act, 1956 for Merger of Sun Pharma Global Inc, a wholly owned foreign subsidiary of our Company, into the Company, Sun Pharmaceutical Industries Ltd without any consideration w.e.f. January 01, 2015 as per the draft Scheme of Amalgamation.
Oct 2014
Sep 2014
Aug 2014
Jul 2014
30 Jul · Business
Hon'ble High Court of Gujarat, at Ahmedabad at its hearing held on July 10, 2014 has approved the Scheme of Arrangement and Reconstruction between Sun Pharmaceutical Industries Limited (SPIL) and Sun Pharma Global FZE (SPGFZE) in the nature of demerger and transfer of the specified Undertaking of SPGFZE to SPIL with effect from the appointed date of May 01, 2013. Further to inform that the certified copy of the High Court order is expected to be received shortly and will be filed with the Registrar of Companies there after as required and the demerger process would get completed on such filing
May 2014